ERBB2 and breast carcinoma: Based on the currently available targeted therapies for breast cancer (also referred to as Endocrine Therapy (ET)) and their superiority to chemotherapy with regards to tolerance, efficacy, and less severe side effects, breast cancer is subdivided into distinct biologic groups based on receptor expression: Estrogen Receptor (ER+), Progesterone Receptor (PR+), those that express the epidermal growth factor receptor 2 (HER2+), and those that do not express either are classified as triple negative BC [30].